Aurobindo Pharma has strengthened its US generics portfolio after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Everolimus tablets in multiple strengths.
The approval covers Everolimus tablets in 0.25 mg, 0.5 mg, 0.75 mg and 1 mg strengths. The product is bioequivalent and therapeutically equivalent to Zortress tablets of Novartis Pharmaceuticals Corp, expanding Aurobindo’s presence in the transplant therapeutics segment.
The approval has been granted to Eugia’s Unit-I facility, with commercial launch in the US market slated for the first quarter of FY27. According to IQVIA MAT data for the twelve months ending December 2025, the approved product addresses an estimated market opportunity of $78 million.
Expanding Specialty Footprint
This marks the 184th Abbreviated New Drug Application (ANDA) approval for the Eugia Pharma Specialities Group (EPSG), including 10 tentative approvals. The milestone underscores Eugia’s growing capabilities in developing and manufacturing complex oral oncology and sterile specialty products for regulated markets.
The addition of Everolimus, an immunosuppressant used in transplant care, broadens the company’s specialty portfolio beyond oncology and injectables, reinforcing its strategy of targeting niche, limited-competition therapies.
Clinical Relevance in Transplant Care
Everolimus tablets are indicated for the prophylaxis of organ rejection in adult kidney transplant patients at low-to-moderate immunologic risk, and in liver transplant patients when administered no earlier than 30 days post-transplant. The therapy is prescribed in combination with other immunosuppressive agents such as basiliximab, reduced-dose cyclosporine or tacrolimus, along with corticosteroids.
Given the critical nature of transplant regimens and the need for long-term immunosuppressive therapy, the segment offers relatively stable demand dynamics compared with more commoditised generic categories.
Strategic Significance
The latest USFDA approval aligns with Aurobindo’s broader strategy of deepening its presence in the US, its largest overseas market, by building scale in differentiated generics and specialty pharmaceuticals. With regulatory clearances from its Eugia facilities steadily rising, the company continues to consolidate its position as a significant supplier of complex generics to regulated markets.
As pricing pressure persists in traditional oral solids, specialty and limited-competition products such as Everolimus are expected to play a critical role in sustaining margins and diversifying revenue streams in the coming years.